- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03587103
Learning Implementation of Guideline-based Decision Support System for Hypertension Treatment: Testing Alternative Antihypertensive Regimens Using ACE-Inhibitors, Calcium Channel Blockers and Diuretics (LIGHT-ACD)
April 14, 2021 updated by: China National Center for Cardiovascular Diseases
This trial aims to compare the efficacy of several guideline-based hypertensive medication regimens initiated with Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker [A], Calcium Channel Blocker [C] and Diuretic [D].
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The LIGHT-ACD Trial is conducted based on the LIGHT trial and aims to compare the efficacy of several guideline-based hypertensive medication regimens initiated with A, C and D for BP control.
Study Type
Interventional
Enrollment (Anticipated)
5000
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xin Zheng, MD, PhD
- Phone Number: +86 60866813
- Email: xin.zheng@fwoxford.org
Study Contact Backup
- Name: Harlan Krumholz, MD, SM
- Phone Number: +86 60866813
- Email: harlan.krumholz@yale.edu
Study Locations
-
-
Henan
-
Beijing, Henan, China
- Completed
- Luoyang Oriental hospital
-
-
Shandong
-
Zoucheng, Shandong, China
- Active, not recruiting
- Yankuang Hospital
-
-
ShenZhen
-
ShenZhen, ShenZhen, China
- Recruiting
- Center for chronic disease control
-
Contact:
- Xin Zheng
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion criteria:
- Age ≥18 years
- Local resident of the community/township who attend a PHC center with DSS treatment of hypertension
- Established diagnosis of essential hypertension, with SBP≥140mmHg and <180mmHg
- Not currently taking any antihypertensive medication or taking only one antihypertensive medication which in not B
Exclusion criteria:
- History of coronary heart disease (i.e., angina, MI, CABG, PCI, >50% stenosis of coronary artery, or positive stress test)
- Physician-diagnosed or self-reported CKD, eGFR <60 mL/min/1.73m2 (if serum creatinine available), or currently on dialysis
- Physician-diagnosed diabetes mellitus
- Physician-diagnosed heart failure
- Physician-diagnosed secondary hypertension
- Intolerance to any class of antihypertensive medications among A, C or D
- Other serious medical illness such as malignant cancer, hepatic dysfunction, et al.
- Currently at the acute phase of any diseases
- Subject is pregnant or breast feeding, or planning to become pregnant or breast feeding during study period
- Patients measured blood pressure at home and the average self-measured home blood pressure <135/85mmHg
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Protocol initiate with A
Eligible participants will be randomized to receive one of the protocols initiated with A, or the protocols initiated with two-drug combination therapy with full dose A.
|
The BP-lowering medication adjustment and titration will follow A-AC-ACD or A-AD-ADC for individuals randomized to A or two-drug combination therapy with full dose of A in their initial medication assignment.
|
EXPERIMENTAL: Protocol initiate with C
Eligible participants will be randomized to receive one of the protocols initiated with C, or the protocols initiated with two-drug combination therapy with full dose C.
|
The BP-lowering medication adjustment and titration will follow C-CA-CAD or C-CD-CDA for individuals randomized to C or two-drug combination therapy with full dose of C in their initial medication assignment.
|
EXPERIMENTAL: Protocol initiate with D
Eligible participants will be randomized to receive one of the protocols initiated with D, or the protocols initiated with two-drug combination therapy with full dose D.
|
The BP-lowering medication adjustment and titration will follow D-DA-DAC or D-DC-DCA for individuals randomized to D or two-drug combination therapy with full dose of D in their initial medication assignment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average change in BP from first visit after the decision support system is installed to 9-month among the individuals who initiated with A, C, and D (population 1) and among those who initiated with two-drug therapy with AC, AD or CD (population 2)
Time Frame: Baseline; 1 year
|
Average change in BP from first visit after the decision support system is installed to 9-month among population 1 (SBP 140-159 mmHg, not currently taking any antihypertensive medications) who initiated with A, C, and D and among population 2 (SBP≥160 mmHg, taking 0-1 antihypertensive medications which is not B; or SBP 140-159mmHg, taking one antihypertensive medication which is not B) who initiated with two-drug therapy with AC, AD or CD, respectively.
|
Baseline; 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of individuals with BP<140/90 mmHg at 9 month.
Time Frame: Baseline; 1 year
|
Proportion of individuals with BP<140/90 mmHg at 9 month among the individuals (population 1: SBP 140-159 mmHg, not currently taking any antihypertensive medications) who initiated with A, C, and D, among those (population 2: SBP≥160 mmHg, taking 0-1 antihypertensive medications which is not B; or SBP 140-159mmHg, taking one antihypertensive medication which is not B) who initiated with two-drug therapy with AC, AD or CD.
|
Baseline; 1 year
|
Proportion of individuals with BP<160/100 mmHg at 9 month.
Time Frame: Baseline; 1 year
|
Proportion of individuals with BP<160/100 mmHg at 9 month among the individuals (population 1: SBP 140-159 mmHg, not currently taking any antihypertensive medications) who initiated with A, C, and D, among those (population 2: SBP≥160 mmHg, taking 0-1 antihypertensive medications which is not B; or SBP 140-159mmHg, taking one antihypertensive medication which is not B) who initiated with two-drug therapy with AC, AD or CD separately.
|
Baseline; 1 year
|
Proportion of individuals who received monotherapy, two-drug treatment, three-drug treatment, or referral at 9 month.
Time Frame: Baseline; 1 year
|
Proportion of individuals who received monotherapy (only in populations 1), two-drug treatment, three-drug treatment, or referral at 9 month among the individuals (population 1: SBP 140-159 mmHg, not currently taking any antihypertensive medications) who initiated with A, C, and D, among those (population 2: SBP≥160 mmHg, taking 0-1 antihypertensive medications which is not B; or SBP 140-159mmHg, taking one antihypertensive medication which is not B) who initiated with two-drug therapy with AC, AD or CD.
|
Baseline; 1 year
|
Proportion of individuals intolerant to each of the four medications.
Time Frame: Baseline; 1 year
|
Proportion of individuals intolerant to each of the four medications among the individuals (population 1: SBP 140-159 mmHg, not currently taking any antihypertensive medications) who initiated with A, C, and D, among those (population 2: SBP≥160 mmHg, taking 0-1 antihypertensive medications which is not B; or SBP 140-159mmHg, taking one antihypertensive medication which is not B) who initiated with two-drug therapy with AC, AD or CD.
|
Baseline; 1 year
|
Proportion of individuals who switched to usual care for any reason.
Time Frame: Baseline; 1 year
|
Proportion of individuals who switched to usual care for any reason among the individuals (population 1: SBP 140-159 mmHg, not currently taking any antihypertensive medications) who initiated with A, C, and D, among those (population 2: SBP≥160 mmHg, taking 0-1 antihypertensive medications which is not B; or SBP 140-159mmHg, taking one antihypertensive medication which is not B) who initiated with two-drug therapy with AC, AD or CD.
|
Baseline; 1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of average change in BP from the first visit after randomization to 9-month between A-AC-ACD and A-AD-ADC, C-CA-CAD and C-CD-CDA, and D-DA-DAC or D-DC-DCA only in population 1, respectively.
Time Frame: Baseline; 1 year
|
Comparison of average change in BP from first visit after randomization to 9-month between protocol A-AC-ACD and A-AD-ADC, C-CA-CAD and C-CD-CDA, and D-DA-DAC or D-DC-DCA among population 1(SBP 140-159 mmHg, not currently taking any antihypertensive medications) .
|
Baseline; 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Xin Zheng, MD, PhD, China National Center for Cardiovascular Disease
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 21, 2019
Primary Completion (ANTICIPATED)
March 30, 2022
Study Completion (ANTICIPATED)
March 30, 2022
Study Registration Dates
First Submitted
July 3, 2018
First Submitted That Met QC Criteria
July 3, 2018
First Posted (ACTUAL)
July 16, 2018
Study Record Updates
Last Update Posted (ACTUAL)
April 15, 2021
Last Update Submitted That Met QC Criteria
April 14, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016-I2M-1-006-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
Clinical Trials on Protocol initiate with A
-
Saint Luke's Health SystemCompletedMagnetic Field Exposure
-
University of Sao PauloRecruitingUrinary IncontinenceBrazil
-
Hospital San Carlos, MadridNot yet recruitingKidney Transplant; ComplicationsSpain
-
NYU Langone HealthNational Institute on Drug Abuse (NIDA)CompletedOpioid-use DisorderUnited States
-
Abbott Medical DevicesCompletedCardiac Arrhythmia | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationSpain, United Kingdom, Germany, Italy, Austria, Czechia, France, Netherlands, Portugal
-
University Hospital, GrenobleCompletedHealthy VolunteerFrance
-
Brigham and Women's HospitalNot yet recruiting
-
Intermountain Health Care, Inc.AbbottActive, not recruitingDiabetes Mellitus, Type 2United States
-
JinyanXingRecruiting
-
The AlfredMonash UniversityRecruitingFibrosis | Lung Diseases | Pancreatic Diseases | Cystic Fibrosis | Genetic Diseases | Respiratory DiseasesAustralia